personalized treatment

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study

Study Overview The study investigates the efficacy of three therapeutic agents—ripertamab, rituximab, and efgartigimod—in treating chronic inflammatory demyelinating polyneuropathy (CIDP),

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study Read Post »

Proteome-wide Mendelian Randomization and Colocalization Nominate CD58, PARP1, and Immune Co-stimulatory Pathways as Genetically Supported Targets for Multiple Sclerosis

Study Overview The research focused on exploring the genetic underpinnings of multiple sclerosis (MS) through advanced analytical methods, specifically Mendelian

Proteome-wide Mendelian Randomization and Colocalization Nominate CD58, PARP1, and Immune Co-stimulatory Pathways as Genetically Supported Targets for Multiple Sclerosis Read Post »

Scroll to Top